Breaks Categories: News

WednesdayNov 30, 2022 11:46 am

NetworkNewsBreaks – Data443 Risk Mitigation Inc. (ATDS) Signs $350K Contract Addition with Global Investment Bank

Data443 Risk Mitigation (OTC: ATDS), a data security and privacy software company for “All Things Data Security,” has announced a contract addition to an existing agreement. The $350,000 addition is with a leading global investment bank and calls for additional licensing for ATDS’s Data443 Data Placement Manager(TM) product. The HPE NonStop server-based application for secure, managed file transfer allows customers to schedule, route, format and securely transfer crucial data over public and private networks. A long-term ATDS customer, the New York City-based bank has more than $2 trillion in assets and uses Data443’s data transfer solution to send and receive tens…

Continue Reading

WednesdayNov 30, 2022 11:42 am

NetworkNewsBreaks – Mona and Friends to Delve Deep into Web 3 with Live Panel and Comedy Show

Mona Shaikh, veteran comedian, producer of Mona&Frens: Web3 Is A Joke and featured on CNN, Forbes and MSNBC, is collaborating with established events producer Stephen Berg and expert event planner Ravneet Kalsi to present Mona and Frens: Web3 is a Joke Web3 Panel and Comedy Show. The event is slated to take place on Dec. 16, 2022, at FameCast in Santa Monica, California, and showcase a web3 expert panel to accelerate learning and offer an unmissable experience with plenty of laughter and networking. Mona and her friends are charging into web3 to tear it up, dive into the nitty gritty…

Continue Reading

WednesdayNov 30, 2022 11:19 am

NetworkNewsBreaks – MICT Inc. (NASDAQ: MICT) Issues Update on Acquisition of Tingo Inc. (TMNA)

MICT (NASDAQ: MICT) previously announced that it is scheduled to complete the acquisition of the operating business and assets of Tingo (OTC: TMNA) by Nov. 30, 2022. This will be achieved through the acquisition of 100% of Tingo’s sole operating subsidiary, Tingo Mobile Limited. In return, MICT is issuing 19.9% of its common stock to Tingo, together with Series A Preferred Stock and Series B Preferred Stock, each of which are convertible into shares of MICT’s common stock upon satisfaction of certain conditions. “The acquisition of Tingo Mobile will not only make MICT significantly profitable from Q4 2022 onwards,” said…

Continue Reading

WednesdayNov 30, 2022 11:09 am

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Forecasts Accelerated Growth in Coming Year

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced its projected revenue growth for the next 12 months. The company has seen accelerated year-over-year growth, and with the increased interest as well as impressive upswing in signed contracts, Knightscope anticipates tripling annualized revenue. In addition, the company released the first in a series of videos. Titled “Rise of the Robots,” the series is designed to share key company updates with KSCP investors and its tens of thousands of followers. “We’ll be filing the 8-K for the combined entity at the end of the year,” said Knightscope…

Continue Reading

WednesdayNov 30, 2022 11:01 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Changes to the Board of Directors

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced the appointments of Dr. Lakshmi P. Kotra and Joseph L. Romano to its board of directors, effective Nov. 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the board of directors. Dr. Kotra, an academic entrepreneur, has contributed to a number of important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He is the recipient of…

Continue Reading

TuesdayNov 29, 2022 3:47 pm

NetworkNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that its CEO Lance Alstodt will be participating at the RHK Capital Disruptive Growth Conference. The event is slated to take place in New York City from Dec. 5-6, 2022, and feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies. Attendees will include seasoned institutional and accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers and select RHK clients. Interested parties should visit https://nnw.fm/Wf4rO to learn more and submit a…

Continue Reading

TuesdayNov 29, 2022 3:01 pm

NetworkNewsBreaks – Advisors Mortgage Group Receives Top Accolade in Asbury Park Press’ Community Choice Awards

Advisors Mortgage Group, based in Ocean Township, New Jersey, today announced that it has been recognized as Best Mortgage Lender in Monmouth and Ocean Counties in the Asbury Park Press’ Official Community Choice Awards. The program polls the local community to select the area’s best businesses and organizations, and, through nominations and voting, winning entities are selected across more than 150 categories. This is the fifth year in a row Advisors Mortgage Group was awarded this accolade in the finance category. “The fact that our company is based in Monmouth County and the community voted for us makes this recognition…

Continue Reading

TuesdayNov 29, 2022 1:53 pm

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its patented DehydraTECH-CBD(TM) has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). According to the update, animal study program EPIL-A21-1 was designed to determine whether DehydraTECH-CBD could provide similar seizure inhibiting efficacy, using an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation (“MES”), at lower doses than were required with Epidiolex, the world’s only commercially approved, CBD-powered anti-seizure drug. In order to minimize adverse side effects, Lexaria is continually searching for the lowest possible efficacious dose levels of…

Continue Reading

TuesdayNov 29, 2022 1:36 pm

NetworkNewsBreaks – MetAlert Inc. (MLRT), Sensio Group Partner to Distribute 3D Monitoring System – RoomMate(TM)

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today announced its entry into a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing RoomMate(TM). A 3D infrared monitoring system, RoomMate is a simple and effective solution for looking after patients without intruding on their personal space. The solution allows for a total “anonymized” supervision and monitoring service using infrared 3D technology with no wearables, cameras or devices needed. “We are very excited about this partnership and remarkable proven technology,” said MetAlert Business Development Director Andrew Duncan.…

Continue Reading

TuesdayNov 29, 2022 11:55 am

NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness. Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive)…

Continue Reading